Inzunza, Hector David
Bristol-Myers Squibb (United States)
3 papers on CoChatORCID 0009-0006-9389-0250
Most cited papers
- Verified
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 4,230
- Verified
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 535
- Verified
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer
Phillips, T., Simmons, P., Inzunza, H. D., Cogswell, J., Novotny, J., Taylor, C., & Zhang, X. (2015) · Applied Immunohistochemistry & Molecular Morphology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 189
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free